Antimicrobial Resistance Surveillance Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Solution (Diagnostic kits, Diagnostic systems, Surveillance software, Services), By Application (Clinical Diagnostics, Public Health Surveillance, Other Applications), By End User (Hospitals & Clinics, Research & Academic Institutes, Others), By Region, and By Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.54 Billion
CAGR (2026-2031)	5.98%
Fastest Growing Segment	Diagnostic kits
Largest Market	North America
Market Size (2031)	USD 9.27 Billion

Market Overview

The Global Antimicrobial Resistance Surveillance Market will grow from USD 6.54 Billion in 2025 to USD 9.27 Billion by 2031 at a 5.98% CAGR. The Global Antimicrobial Resistance Surveillance Market encompasses the specialized diagnostic instruments and software platforms used to systematically track and analyze pathogen susceptibility to antimicrobial drugs. The primary drivers fueling market growth include the urgent necessity to combat the escalating prevalence of multidrug-resistant organisms and the global implementation of rigorous antimicrobial stewardship programs. Furthermore, substantial government initiatives and funding directed toward strengthening laboratory infrastructure and ensuring data interoperability are actively accelerating the deployment of these critical monitoring systems across healthcare networks.

Significant barriers remain regarding the substantial financial investment required to install and maintain sophisticated surveillance technologies, which impedes adoption in resource-constrained environments. This cost factor often limits the expansion of automated reporting capabilities in developing regions where technical infrastructure is lacking. According to the World Health Organization, in 2025, 127 countries had formally enrolled in the Global Antimicrobial Resistance and Use Surveillance System to support standardized monitoring efforts.

Key Market Drivers

The rising prevalence of multi-drug resistant infections serves as the primary catalyst for the Global Antimicrobial Resistance Surveillance Market, necessitating an urgent expansion of diagnostic capabilities. As pathogens evolve to withstand standard treatments at an accelerated rate, healthcare systems are compelled to adopt advanced monitoring frameworks that can detect resistance patterns in real time. This escalation in biological threats drives the demand for high-throughput systems capable of informing empirical therapy and containment strategies. According to The Lancet, September 2024, in the 'Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050', bacterial antimicrobial resistance is projected to result in more than 39 million direct deaths globally between 2025 and 2050. Consequently, diagnostic developers are prioritizing technologies that identify emerging resistance markers to mitigate this projected mortality burden.

Increased public and private funding for AMR research and infrastructure constitutes the second critical driver, directly addressing the resource intensity of establishing comprehensive surveillance networks. National governments and international bodies are actively financing the modernization of laboratory capabilities to close data gaps across human, animal, and environmental health sectors. According to the UK Government, May 2024, in the 'UK announces funding to boost global fight against antimicrobial resistance', a financial package worth £85 million was pledged to support international efforts, including the strengthening of surveillance systems in the Caribbean and Africa. Despite these investments, gaps in specific monitoring domains persist; according to the Global Coalition on Aging, February 2024, in the '2024 AMR Preparedness Index Progress Report', only four of the eleven high-income countries analyzed were performing regular monitoring of water for antimicrobial resistance genes, highlighting the sustained market opportunity for expanded environmental surveillance solutions.

Download Free Sample Report

Key Market Challenges

The substantial financial investment required to install and maintain diagnostic technologies constitutes a primary restraint on the growth of the antimicrobial resistance surveillance market. This cost barrier significantly limits the adoption of automated reporting systems, particularly in regions with restricted healthcare budgets where allocating funds for digital infrastructure is challenging. Consequently, many healthcare facilities in developing economies continue to rely on manual data collection processes rather than integrating digital tracking platforms, effectively narrowing the addressable market for diagnostic manufacturers.

The inability to secure necessary budget allocations directly hampers the scalability of global surveillance networks. When medical institutions cannot afford the initial capital expenditure or the ongoing operational costs, vendors face reduced demand in high-burden regions. According to the World Health Organization, in 2024, only 11 percent of countries had allocated dedicated financial resources to implement their national antimicrobial resistance action plans. This lack of dedicated financing ensures that a large segment of the potential global market remains untapped, stalling the widespread deployment of standardized monitoring instruments.

Key Market Trends

The widespread adoption of Whole Genome Sequencing (WGS) is significantly transforming the Global Antimicrobial Resistance Surveillance Market by enabling precise characterization of pathogen genetics beyond traditional phenotypic methods. This technological shift allows public health networks to rapidly identify transmission clusters, track the evolution of multi-drug resistant clones, and distinguish between relapse and reinfection with high accuracy. As laboratories increasingly prioritize genomic data to inform containment strategies, the integration of molecular diagnostics is becoming a standard component of national monitoring infrastructures. According to the European Centre for Disease Prevention and Control, November 2025, in the 'Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report for 2024', 84 percent of participating laboratories across 26 countries reported utilizing molecular methods, including PCR and whole-genome sequencing, to select isolates for advanced antimicrobial susceptibility testing.

The integration of Artificial Intelligence and Machine Learning represents a parallel trend revolutionizing how surveillance data is processed and utilized for predictive analytics. These advanced computational tools are being deployed to analyze vast, complex datasets from diverse sources, enabling the early detection of emerging resistance hotspots and the optimization of empirical prescribing practices. By automating the identification of resistance patterns, AI-driven platforms significantly reduce the time required to generate actionable insights, thereby attracting substantial investment into the development of smart surveillance ecosystems. According to Alliance News, November 2025, in the 'GSK and Fleming Initiative in GBP45 million AI-driven research push', a new strategic partnership committed £45 million to fund approximately 50 scientific roles dedicated to utilizing advanced AI and supercomputing for tracking and mitigating drug-resistant infections.

Segmental Insights

Diagnostic kits are currently positioned as the fastest-growing segment in the Global Antimicrobial Resistance Surveillance Market, driven by the increasing necessity for rapid and accurate pathogen detection. Healthcare facilities are prioritizing these tools to facilitate immediate clinical decision-making and support antimicrobial stewardship programs. This growth is further accelerated by global mandates from entities such as the World Health Organization, which emphasize the expansion of laboratory capacity for early resistance monitoring. As a result, the adoption of molecular and rapid testing solutions is rising significantly to address the urgent challenge of tracking multi-drug resistant organisms effectively.

Regional Insights

North America holds a dominant position in the Global Antimicrobial Resistance Surveillance Market due to favorable government policies and strong healthcare infrastructure. The region benefits from active monitoring initiatives led by established institutions such as the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration. These organizations facilitate comprehensive data collection through collaborative programs like the National Antimicrobial Resistance Monitoring System. Additionally, the high adoption of diagnostic technologies allows for efficient tracking of resistance patterns, creating a stable environment for market expansion and continuous surveillance improvements.

Recent Developments

• In November 2024, iFAST Diagnostics announced that it had secured $6.5 million in seed funding to advance its rapid antimicrobial susceptibility testing technology. The investment round was led by KHP Ventures and included participation from several other key industry investors. The company stated that the capital would be utilized to conduct clinical trials and bring its innovative microchip-based platform to market in the UK, US, and Europe. This breakthrough technology was designed to analyze bacteria electrically to provide results significantly faster than traditional methods. By enabling quicker identification of effective antibiotics, the company aimed to improve patient outcomes and reduce the misuse of antimicrobials.
• In September 2024, Roche announced the extension of its strategic partnership with the INCubator for Antibacterial Therapies in Europe (INCATE) until 2027. This continued collaboration reinforced the company's dedication to fostering innovation in the fight against drug-resistant bacterial infections. Through this agreement, the company committed to supporting early-stage ventures and academic innovators in developing new antibacterial treatments and diagnostics. The partnership aimed to bridge the critical gap between basic research and industrial development, ensuring a sustainable pipeline of solutions to address the escalating challenge of antimicrobial resistance. This initiative highlighted the vital role of public-private collaborations in strengthening the global response to the AMR crisis.
• In June 2024, bioMérieux received 510(k) clearance from the U.S. FDA for its VITEK® REVEAL™ AST System. This modular diagnostic instrument was developed to deliver actionable antimicrobial susceptibility testing results for Gram-negative bacteria directly from positive blood cultures in an average of approximately six hours. By seamlessly integrating into the company's comprehensive portfolio for bloodstream infections and sepsis, the system was positioned to facilitate same-day treatment decisions for critically ill patients. This product launch underscored the company’s commitment to supporting antimicrobial stewardship programs and addressing the urgent global threat of antimicrobial resistance through innovative surveillance and diagnostic solutions.
• In February 2024, Selux Diagnostics announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Positive Blood Culture (PBC) Separator. This regulatory approval enabled the company to offer a unified platform capable of providing rapid antimicrobial susceptibility testing (AST) results directly from positive blood cultures, eliminating the need for a time-consuming subculture step. This technological advancement was designed to significantly accelerate the selection of targeted antibiotic therapies for patients. By streamlining the diagnostic workflow, the company aimed to combat the spread of superbug infections and preserve the efficacy of essential antibiotics within the Global Antimicrobial Resistance Surveillance Market.

Key Market Players

• Luminex Corporation
• Thermo Fisher Scientific Inc
• Accelerate Diagnostics, Inc.
• Liofilchem S.r.I.
• Becton, Dickinson, and Company
• Biomerieux Inc.
• Bruker Corp.
• Danaher Corporation
• Merck KgaA
• Abbott Laboratories Inc.

By Solution	By Application	By End User	By Region
Diagnostic kits Diagnostic systems Surveillance software Services	Clinical Diagnostics Public Health Surveillance Other Applications	Hospitals & Clinics Research & Academic Institutes Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Antimicrobial Resistance Surveillance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Antimicrobial Resistance Surveillance Market, By Solution:

• Diagnostic kits
• Diagnostic systems
• Surveillance software
• Services

• Antimicrobial Resistance Surveillance Market, By Application:

• Clinical Diagnostics
• Public Health Surveillance
• Other Applications

• Antimicrobial Resistance Surveillance Market, By End User:

• Hospitals & Clinics
• Research & Academic Institutes
• Others

• Antimicrobial Resistance Surveillance Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE